Midostaurin - the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10465360" target="_blank" >RIV/00064165:_____/22:10465360 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/22:10465360

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=rvftc_dahW" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=rvftc_dahW</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.32383/appdr/159470" target="_blank" >10.32383/appdr/159470</a>

Result language

angličtina

Original language name

Midostaurin - the First Targeted Therapy Drug for Patients with Acute Myeloid Leukaemia with FLT3 Mutation

Original language description

The prognosis for patients with acute myeloid leukemia (AML) varies depending on genetic factors. The presence of mutations in the FMS-like tyrosine kinase 3 (FLT3) gene is found in approximately 30% of AML patients. Midostaurin, a first-generation multi-targeted tyrosine kinase inhibitor, is the first FLT3 inhibitor approved for the treatment of newly diagnosed AML patients with the FLT3 mutation in combination with standard induction and consolidation chemotherapy. However, as numerous clinical trials have shown, the list of indications for this drug is likely to be extended. Midostaurin can be administered orally, which improves the patient&apos;s comfort during treatment. In general, it has a favorable safety profile, but interactions with other drugs, such as strong CYP3A4 inhibitors or inducers, which are often used in the concomitant therapy of AML patients, may lead to changes in midostaurin plasma concentrations. In consequence, such interactions may increase the toxicity of the treatment or reduce its therapeutic effect. This review aims to summarise the current knowledge on midostaurin, i.e. its mechanisms of action, dosage, adverse effects, mechanisms of resistance, and limitations to its use. Due to the growing importance of the management of drug-drug interactions mediated via cytochrome CYP3A4, the main focus of this study is the pharmacokinetics of midostaurin and the variability of its plasma concentrations. The authors emphasize therapeutic drug monitoring with midostaurin as a potential method of managing AML patients with FLT3 mutation.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Acta Poloniae Pharmaceutica

ISSN

0001-6837

e-ISSN

2353-5288

Volume of the periodical

79

Issue of the periodical within the volume

6

Country of publishing house

PL - POLAND

Number of pages

8

Pages from-to

777-784

UT code for WoS article

000992684900001

EID of the result in the Scopus database

2-s2.0-85151408093